May 23, 2007 —Thoratec Corp. has announced it has completed enrollment in the randomized portion of the Destination Therapy (DT) arm of its Pivotal trial for the HeartMate II by enrolling 200 patients on a randomized basis as called for in the trial protocol.
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now